Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Forli, Italy Clinical Trials

A listing of Forli, Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (10) clinical trials

Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

This study will evaluate the safety and efficacy of MK-4280 in combination with pembrolizumab (MK-3475) in participants with hematological malignancies: classical Hodgkin lymphoma (cHL) diffuse large B-cell lymphoma (DLBCL) indolent non-Hodgkin lymphoma (iNHL) The study will have 2 phases: a safety lead-in and an efficacy expansion phase. The recommended Phase …

Phase

6.69 miles

Learn More »

Study of IMGN632 in Patients With Relapse/Refractory AML BPDCN ALL Other CD123+ Hem Malignancies

The study comprises a dose escalation phase followed by a dose expansion phase to further characterize the safety profile and confirm the MTD. IMGN632 will be administered IV on Day 1 of each cycle, with cycles repeating every 21 days. Treatment will continue for up to 2 cycles (6 weeks) …

Phase

6.69 miles

Learn More »

Safety Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

The total study duration per patient is up to 28 months including an up to 28 days screening period, an up to 24 months treatment period, and a 3 months safety follow up period.

Phase

6.69 miles

Learn More »

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

This is a multicenter study that includes two phases: A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose escalation of Romidepsin (8, 10, 12, 14 mg). The dose level …

Phase

6.69 miles

Learn More »

A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

This study is a phase I/II, open-label study in patients with relapsed indolent non-Hodgkin lymphoma. Part A of the study included a phase I dose escalation to define the maximum tolerated / recommended dose for expansion of (177Lu)-lilotomab (Betalutin), and a phase IIa part to evaluate safety and preliminary efficacy. …

Phase

6.69 miles

Learn More »

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Breast cancer is a major cause of cancer mortality, second only to lung cancer as a cause of cancer death in women. The five-year survival rate for localized breast cancer has increased from 80 percent in the 1950s to 98 percent today. However, the mortality rate in the most advanced …

Phase

6.69 miles

Learn More »

Safety Tolerability Pharmacokinetics and Activity of K0706

Part A ( for Healthy volunteers) of the study is completed Part B (for CML subject ) of the study is ongoing only in India, other countries completed. (Recruitment for Part B initiated in April 2017) Part C of study in subjects with CML is on-going in all mentioned countries …

Phase

6.69 miles

Learn More »

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 (olutasidenib) as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will utilize an open-label design of …

Phase

6.69 miles

Learn More »

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

The Phase 1 portion of the study will cover the dose escalation portion of the study. This will then be followed by the Phase 2 portion of the study, which will treat participants with the dose of loncastuximab tesirine determined in the Phase 1 portion of the study. The ibrutinib …

Phase

6.69 miles

Learn More »

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

The Part A of the study is currently not accepting healthy volunteers as the recruitment for the part A has completed.

Phase

6.69 miles

Learn More »